MediWound will release third quarter 2025 financial results on November 20, 2025, followed by a conference call.
Quiver AI Summary
MediWound Ltd. announced that it will release its financial results for the third quarter of 2025 on November 20, 2025. The company’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. MediWound, a biotechnology firm focused on enzymatic therapies for tissue repair, offers the FDA-approved product NexoBrid® for the treatment of thermal burns and is developing another therapy, EscharEx®, for chronic wound debridement. Interested parties can access the call using provided dial-in details or through a webcast link, and an archived version will be available on their website.
Potential Positives
- MediWound is preparing to report its third quarter financial results, which can provide transparency and insight into its financial health and performance in a timely manner.
- The management conference call and webcast following the earnings release offer an opportunity for real-time engagement with stakeholders and investors, enhancing communication and investor relations.
- The mention of EscharEx® as a late-stage investigational therapy suggests ongoing pipeline advancement, indicating potential future growth and revenue opportunities for the company.
- The established FDA approval of NexoBrid® in multiple international markets reflects regulatory confidence in MediWound’s products and showcases the company’s global market presence.
Potential Negatives
- The press release does not provide any details about the financial performance or any specific expectations for the upcoming quarter, which may lead to concerns about the company's financial health.
- There is a lack of information regarding the progress or status of the investigational therapy EscharEx, which could raise questions about the company's development pipeline.
- The timing of the conference call, which is scheduled for a date that is over two weeks away, may be perceived as a delay in addressing investor concerns, particularly if there are pressing issues that need to be addressed sooner.
FAQ
When will MediWound report its Q3 2025 financial results?
MediWound will report its Q3 2025 financial results on Thursday, November 20, 2025.
What time is the MediWound conference call scheduled?
The conference call is scheduled for 8:30 a.m. Eastern Time on November 20, 2025.
How can I access the MediWound conference call?
Participants can dial the toll-free number or follow the webcast link provided in the press release.
Where can I find the archived version of the webcast?
An archived version of the webcast will be available in the Investors section of the MediWound website.
What products does MediWound focus on developing?
MediWound focuses on enzymatic therapies for non-surgical tissue repair, including NexoBrid® and EscharEx®.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDWD Hedge Fund Activity
We have seen 31 institutional investors add shares of $MDWD stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MEITAV INVESTMENT HOUSE LTD added 260,116 shares (+825.7%) to their portfolio in Q3 2025, for an estimated $4,687,290
- PRICE T ROWE ASSOCIATES INC /MD/ added 215,180 shares (+134.7%) to their portfolio in Q2 2025, for an estimated $4,168,036
- ROSALIND ADVISORS, INC. removed 99,832 shares (-19.7%) from their portfolio in Q2 2025, for an estimated $1,933,745
- BLACKROCK, INC. removed 43,645 shares (-9.2%) from their portfolio in Q2 2025, for an estimated $845,403
- STATE STREET CORP added 38,748 shares (+53.7%) to their portfolio in Q2 2025, for an estimated $750,548
- MILLENNIUM MANAGEMENT LLC added 38,499 shares (+inf%) to their portfolio in Q2 2025, for an estimated $745,725
- BALYASNY ASSET MANAGEMENT L.P. removed 30,038 shares (-28.4%) from their portfolio in Q2 2025, for an estimated $581,836
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDWD Analyst Ratings
Wall Street analysts have issued reports on $MDWD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/22/2025
To track analyst ratings and price targets for $MDWD, check out Quiver Quantitative's $MDWD forecast page.
Full Release
MediWound to Report Third Quarter 2025 Financial Results
Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time
YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2025 on Thursday, November 20, 2025.
Following the release, the Company’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
Dial-in and call details are as follows:
Conference Call & Webcast Details
Toll-Free: 1-844-676-8833
Israel: 1-809-212373
International: 1-412-634-6869
Webcast:
Webcast Link
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid ® , is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx ® , a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter) .
MediWound Contacts: Media Contact:
Hani Luxenburg Daniel Ferry Ellie Hanson
Chief Financial Officer Managing Director Partner
MediWound Ltd. LifeSci Advisors, LLC FINN Partners for MediWound
[email protected]
[email protected]
[email protected]
